Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONTY $1.89 0.1600 +9.25%
MYGN $37.22 2.2200 +6.34%
AGIO $72.44 4.1907 +6.14%
NWBO $5.08 0.2400 +4.96%
AMGN $143.70 6.1850 +4.50%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CVM $0.69 -0.1568 -18.45%
INO $11.41 -0.7800 -6.40%
APRI $1.55 -0.0899 -5.48%
CERU $4.26 -0.2300 -5.12%
SNSS $1.43 -0.0750 -5.00%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Expert Q&A: Does Radiation From Dental X-Rays Cause Thyroid Cancer?

(CNN Health) Mar 30, 2011 - I have heard that there is an increase in the number of people getting thyroid cancer. Is this true and is radiation from dental X-rays a cause for the increase?
read article 

Benefits of Radiation Therapy Outweigh Risks of a Second Cancer: Study

(Bloomberg/Businessweek) Mar 30, 2011 - The odds a second cancer will develop after radiation treatment for a first cancer are relatively low, U.S. National Cancer Institute researchers report.
read article 

Evidence Ties Smoking to Throat, Stomach Cancer

(FOX News/Reuters) Mar 30, 2011 - Smokers face an increased risk of certain types of throat and stomach cancers, even years after they quit, a new study finds.
read article 

Study Reveals No Impact of Age on Outcome in Chronic Myeloid Leukemia Patients Treated With Imatinib

(ASH) Mar 30, 2011- While the median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years old and incidence increases dramatically with age, limited data are available about the long-term outcome for older patients treated with imatinib, the standard first-line therapy used to treat CML.
read press release 

Amgen, Takeda Lung Cancer Drug Failed to Extend Life in Late-Stage Testing

(Bloomberg) Mar 30, 2011 - An experimental treatment for lung cancer made by Amgen Inc. and Takeda Pharmaceutical Co. failed to help patients live longer in a late-stage study needed for regulatory approval.
read article 

Amgen, Takeda Drug Fails Advanced Lung-cancer Study

(Reuters) Mar 30, 2011 - Amgen Inc and Takeda Pharmaceutical Co Ltd said their experimental drug, motesanib, had failed to improve overall survival in a late-stage study of patients with advanced lung cancer.
read article 

Merck KGaA Takes New Aim at Lung Cancer Market

(Reuters) Mar 30, 2011 - Merck KGaA made a new attempt at winning approval for the use of its potential blockbuster drug Erbitux against lung cancer, targeting a quarter of the patients it had initially tried to address.
read article 

Merck, Novartis Blood Cancer Drugs May Shrink Child Tumors, Study Finds

(Bloomberg) Mar 29, 2011 - A family of blood cancer drugs made by Merck & Co. and Novartis AG may help treat a rare and incurable disease that causes large tumors to form in the chest, head and neck of children, Harvard researchers report.
read article 

Medicare in Spotlight on Cancer Drug

( Mar 29, 2011 - If anything is too expensive for Medicare, it just might be a prostate cancer therapy that costs $93,000 and gives men, on average, an extra four months to live.
read article 

Ariad Pharmaceuticals Not For Sale: CEO

(Reuters) Mar 29, 2011 - Ariad Pharmaceuticals, whose stock is trading at near five-year highs, is not looking to sell itself and is in partnership talks with large pharmaceutical companies in Japan for its leukemia drug, its chief executive said.
read article 

Merck: Erbitux Indication Extension Submitted for First-Line Advanced or Metastatic NSCLC in the EU

(Merck KGaA) Mar 30, 2011 – Merck KGaA announced today that it has submitted an indication extension to the European Medicines Agency (EMA) for the approval of Erbitux® (cetuximab) in combination with standard first-line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with high epidermal growth factor receptor (EGFR) expression.
download pdf  

Top-Line Results Announced of Pivotal Phase 3 Motesanib Trial in Advanced Non-Squamous Non-Small Cell Lung Cancer Patients

(Amgen) Mar 30, 2011 – Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer (NSCLC). The trial did not meet its primary objective of demonstrating an improvement in overall survival (OS) (hazard ratio 0.90, 95 percent CI 0.78 - 1.04, p=0.14).
read press release 

Study Finds Conflicts Among Panels’ Doctors

(New York Times) Mar 29, 2011 - Doctors with private financial conflicts of interest dominated some of the panels that wrote guidelines on cardiovascular health in recent years, according to a medical journal study released on Monday.
read article (paid subscription required) 

Hospitals Increasingly Offer Palliative Care

(Washington Post) Mar 28, 2011 - If you’ve never heard of palliative care, you’re not alone. In a recent survey , only 24 percent of people said they were familiar with the term. Palliative care isn’t nearly as well known as, say, hospice care; in fact, people often confuse the two.
read article (free registration required) 

In Astra Case, Ginsburg Again Shows Disdain For Some Litigation

(Forbes/Full Disclosure Blog) Mar 29, 2011 - In what must be a distressing trend for trial lawyers, U.S. Supreme Court Justice Ruth Bader Ginsburg penned a unanimous decision, released today, that rejected private lawsuits over alleged drug overpricing.
read article 

Rising Reports of Bad Reactions to Drugs

(Reuters) Mar 28, 2011 - Official reports of negative reactions to prescription drugs have increased dramatically over the last decade, according to a new study.
read article 

The Cost of Drug Shortages

(WSJ/Health Blog) Mar 28, 2011 - An ongoing shortage of prescription drugs is costing hospitals at least $200 million annually and puts patients at risk of medication errors, according to an analysis and survey conducted by the Premier health-care alliance, a group of hospitals and other health-care providers.
read article (paid subscription required) 

Cancer Risk Is Low, But Possible in Airport Scanners

(CNN/The Chart Blog) Mar 28, 2011 - If you’ve traveled through an airport lately, you’ve probably seen one of the new full body X-ray machines called a backscatter, a type of imaging technology used by the Transportation Security Administration to identify concealed items.
read article 

Hit By the Reality of Cancer Treatment

(NYT/Well Blog) Mar 29, 2011 - As the doctor rattled off my wife’s cancer history, I realized how badly I had misjudged what the year would be like, and how poorly prepared I was for it, writes Dr. Peter Bach.
read article (paid subscription required) 

Pinnacle Biologics Acquires PHOTOFRIN(R) and PHOTOBARR(R), Novel Photodynamic Therapy for Treating Various Types of Cancer

(Yahoo! Finance) Mar 29, 2011 - Pinnacle Biologics, Inc., a privately held specialty bio-pharmaceutical company announced today the global acquisition of PHOTOFRIN® and PHOTOBARR® from Axcan Pharma, Inc.
read article 

Evidence and Logic Clash When It Comes to Small Cancer Tumours

(The Globe and Mail) Mar 27, 2011 - When evidence-based practice in medicine persuades government to deny a young mother with breast cancer a drug that offers a real chance of saving her life, something has gone wrong with evidence-based medicine.
read article 

Kentucky Medicaid Considers Restricting Three Cancer Drugs

(Louisville Courier-Journal/AP) Mar 28, 2011 - Health officials in Kentucky are considering a move to restrict cancer medications that Medicaid patients can receive without prior approval.
read article 

This Week’s Health Industry News

(NYT/Prescriptions Blog) Mar 28, 2011 - The Centers for Medicare and Medicaid Services is scheduled to announce by Wednesday its coverage for Dendreon’s Provenge, a $93,000 prostate cancer drug treatment.
read article (paid subscription required) 

Report From Results of a Successful Phase II Study for DARA's KRN5500 at ADEPT

(TheStreet) Mar 29, 2011 - Researchers Christine K. Moore, PhD, Susan E. Spruill, PStat, and Linda G. Jett, MSN, reported the results from a trial evaluating the safety and tolerance of a new medication, KRN5500, being developed by DARA BioSciences. In earlier studies conducted by the National Cancer Institute, KRN5500 showed promise for relieving neuropathic pain which often afflicts cancer patients.
read article 

Nordion Reports TheraSphere(R) Phase II Clinical Trial Results at Society of Interventional Radiology

(Nordion) Mar 28, 2011 - Nordion Inc., a leading provider of products and services to the global health science market, today shared results from the first multi-site, Phase II clinical trial to evaluate TheraSphere(R) for treatment of metastatic liver cancer.
read press release